Skip to main content

Table 2 Pharmacokinetic parameters

From: A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

 

0.06 mg/kg ALT-836

0.08 mg/kg ALT-836

0.1 mg/kg ALT-836

t1/2 term., hour

18.5 ± 5.9

22.6 ± 3.1

22.6 ± 6.2

Cmax, ng/ml (nM)

1,300 ± 560 (8.6)

1,490 ± 340 (9.9)

1,800 ± 250 (12.0)

Vd, ml/kg

46.1 ± 13.1

47.7 ± 16.0

54.5 ± 6.6

Cl, ml/hr/kg

1.9 ± 1.0

1.5 ± 0.7

1.8 ± 0.4

AUCINF, hr·ng/ml

39,000 ± 24,200

59,900 ± 20,500

59,900 ± 16,600

  1. t1/2 term., terminal half-life; Cmax, maximum serum concentration; Vd, volume of distribution; Cl, total body clearance: AUCINF, area under the drug concentration versus time curve extrapolated to infinity
  2. Values are means ± SD
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us